Progyny (PGNY Quick QuotePGNY - Free Report) reported $350.51 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.3%. EPS of $0.55 for the same period compares to $0.48 a year ago.

The reported revenue represents a surprise of +0.38% over the Zacks Consensus Estimate of $349.19 million. With the consensus EPS estimate being $0.51, the EPS surprise was +7.84%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Progyny performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Utilization - Female Only: 0.5% versus 0.5% estimated by two analysts on average.
• Revenue- Pharmacy benefit services revenue: $120.3 million versus $124.2 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +1.2% change.
• Revenue- Fertility benefit services revenue: $230.2 million versus the two-analyst average estimate of $225 million. The reported number represents a year-over-year change of +7.6%.

View all Key Company Metrics for Progyny here>>>

Shares of Progyny have returned +2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.